Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (10): 1116-1120.

Previous Articles     Next Articles

Experimental study on the rationality of amiloride off-label use in treating primary aldosteronism

TANG Hong-mei1, TU Xing2, CHAI Yu-na2   

  1. 1 First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405,Guangdong,China;
    2 Guangzhou University of Chinese Medicine, Guangzhou 510006,Guangdong,China
  • Received:2013-09-23 Revised:2014-07-15 Online:2014-10-26 Published:2014-10-29

Abstract: AIM: To study the feasibility and security of amiloride off-label use in treating primary aldosteronism in order to provide reasonable basis for its treatment. METHODS: Using the primary aldosteronism (short for PA) rat model caused by Mini-Osmotic pump contain aldosterone as the research objects, then given the high, medium and low dose of amiloride for some days. Then observing therapeutical effect and the ADR on PA, and investigating the relationship of aldosterone's level and its secrete rate between the amiloride and aldosterone. RESULTS: The content of potassium ion in the urine of model group was far higher than the normal group, but in the blood it was far lower than normal group. After giving amiloride, the content of potassium ion in the urine of rats decreased, the content of sodion increased, while comparing to the indexes in blood, the content of potassium ion increased, and the content of sodion decreased. But white giving high dose of amiloride, the content of potassium ion in the blood increased significantly, which is more than normal rats. CONCLUSION: Amiloride can be off-label used in treating of primary aldosteronism, but when we give amiloride to patients we should pay much attention to the potassium in patients' blood.

Key words: amiloride, off-label use, primary aldosteronism(PA), aldosterone, serum potassium

CLC Number: